WELCOME!
to IMGT/mAb-DB
THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM®
IMGT
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF


IMGT/mAb-DB ID 44
INN gemtuzumab
INN Number 8024
INN Prop. List 83 (2000)
INN Rec. List 45 (2001)
Common name CMA-676 (ADC), hP67.6 (naked), CDP-771, WAY-CMA-676, hP67.6-calicheamicin (ADC),, MYLOTARG® (gemtuzumab ozogamicin)
Proprietary name
Species Humanized
IMGT receptor type IG
Format (legend)
Receptor identification IgG4 - kappa
Radiolabelled / Conjugated / Fused conjugated with N-acetyl-gamma calicheamicin
IMGT/2Dstructure-DB
IMGT/3Dstructure-DB
Specificity target name and species CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) [Humanized]
Development Technology
Origin clone species Mus musculus
Origin clone name P67.6

Company Pfizer (New York NY USA)
Expression system NS0 mouse myeloma cells
Application Therapeutic
Clinical domain Hematology; Oncology
Mechanism of action
Clinical indication Acute myeloid leukemia (AML) (CD33 positive)
Development status Phase III
Regulatory agency status and year
  • FDA withdrawal (by Pfizer, on concerns about the product's safety and absence of clinical benefit in trials) June 01, 2010
  • FDA approval May 17, 2000

Clinical trials 102 studies found, 31 recruiting
Authority decisions
  • EMA: EMEA/37537/2008 (refusal of the marketing authorisation April 14, 2008)
External links
IMGT citations
  • Information provided by Mitchell Reff, IDEC Pharmaceuticals.
  • Marie-Paule Lefranc, IMGT (26/12/2005).
IMGT notes
  • Calicheamicin is a cytotoxin antitumor antibiotic, isolated from fermentation of a bacterium, Micromonospora echinospora, subsp. calichensis.
  • Pfizer (New York NY USA) acquiered Wyeth Pharmaceuticals (Madison NJ USA) in 2010
  • Although gemtuzumab (#44, INN 8024 (83)(45)) has been used, conjugated with ozogamicin and marketed as MYLOTARG┬«, the INN for 'gemtuzumab ozogamicin' (#649, INN 10315 (115) (77)) has only been published in 2016 (L115). Updates for gemtuzumab ozogamicin posterior to 2016 are reported in the entry #649 gemtuzumab ozogamicin INN number 10315 (115).
Biosimilars
    Format legend:

    © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
    European Commission umontpellier CNRS